Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients.

Trial Profile

Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2012

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top